The treatment paradigm for hematologic malignancies has shifted undoubtedly over the past two decades. What was once a largely histomorphology-driven discipline has become one of the most molecularly stratified fields in oncology, where genomic characterization at diagnosis is not merely informative but functionally essential. Treatment eligibility, sequencing, intensity, and response assessment are all anchored to molecular biomarker status. According to ELN and WHO 2022 guidelines, over 80% of AML cases harbor at least one actionable mutation when comprehensively profiled [1,2]. Molecular classification now substantially refines morphological and cytogenetic risk stratification, with direct implications for therapeutic decision-making across virtually all hematologic entities.
NPM1 Mutations & Menin Inhibitors
NPM1 mutations represent the most frequent somatic alteration in adult Acute Myeloid Leukemia (AML), occurring in approximately 25–35% of cases [3]. In NPM1-mutated AML — and in KMT2A-rearranged leukemias — Menin functions as a scaffold sustaining aberrant HOX gene expression and blocking myeloid differentiation [3]. Menin inhibitors disrupt this oncogenic complex, restoring differentiation. Revumenib received dual FDA approval in 2024–2025 for relapsed/refractory KMT2A-rearranged and NPM1-mutated acute leukemia based on the phase 1/2 AUGMENT-101 trial, achieving CR+CRh rates of 21% and 26% respectively [3]. Investigational agents ziftomenib and enzomenib have shown promising results, potentially expanding this class further [3].
Biomarker role: NPM1 and KMT2A mutational status are crucial supporting therapeutic eligibility. Quantitative MRD monitoring throughout treatment provides a validated surrogate for treatment depth, informing consolidation strategy and transplant timing; persistent MRD positivity after consolidation is strongly associated with relapse [3].
BCR-ABL1 & TKI Inhibitors
BCR-ABL1 remains the paradigmatic oncogene-targeted therapy model. Three generations of TKIs provide a structured clinical framework: imatinib established proof-of-concept; dasatinib and nilotinib overcome most resistance mutations; ponatinib (FDA-approved) addresses the T315I gatekeeper mutation. Asciminib, a STAMP inhibitor with a distinct allosteric mechanism, olverembatinib, and vamotinib further expand therapeutic options for relapsed or TKI-intolerant patients [4].
Biomarker role: BCR-ABL1 detection confirms diagnosis and has a strategic role into the definition of TKI eligibility. Quantitative transcript monitoring on the International Scale provides structured response milestones. Kinase domain mutation analysis at relapse is mandatory to identify the specific resistance variant and select the appropriate next-generation agent.
PML-RARA & Differentiation Agents
Acute Promyelocytic Leukemia (APL), defined by t(15;17) and the resulting PML::RARA fusion, was most likely the first hematologic malignancy cured through mechanism-based targeted therapy. ATRA targets the RARA moiety, relieving the differentiation block, whereas arsenic trioxide (ATO) binds directly to the PML moiety, inducing its proteasomal degradation. The combination achieves cure rates exceeding 90% in low-to-intermediate risk APL [5]. The phase 3 APOLLO trial (JCO 2025) extended this paradigm to high-risk APL, demonstrating superior 2-year event-free survival (88% vs. 71%) and significantly fewer molecular relapses compared to standard ATRA-chemotherapy, supporting chemotherapy-free induction in this historically challenging subgroup [6].
Biomarker role: Molecular confirmation of PML::RARA at diagnosis is both a diagnostic and a therapeutic urgency trigger — empirical ATRA initiation on clinical suspicion is recommended given the risk of fatal coagulopathy. Post-consolidation MRD monitoring is recommended per ELN guidelines, with persistent positivity indicating high relapse risk and guiding salvage decisions [5,6].
CBFB-MYH11 [inv(16)] & RUNX1-RUNX1T1 (AML1-ETO) — Core Binding Factor AML
These two rearrangements define core binding factor (CBF) AML, collectively accounting for approximately 15–20% of adult AML and generally classified as ELN favorable-risk. Both fusions disrupt the core binding factor transcriptional complex, suppressing differentiation (7). For CBFB::MYH11-positive AML, gemtuzumab ozogamicin (GO, anti-CD33 ADC) improves outcomes when added to high-dose cytarabine-based consolidation and is incorporated in several international protocols [7]. KIT mutations — particularly exon 17 — are found in a significant proportion of CBF-AML patients and are independently associated with adverse prognosis within the otherwise favorable-risk group [7]. No approved therapy directly targeting RUNX1::RUNX1T1 exists to date, with PROTACs and cooperating mutation exploitation under active investigation [8]
Biomarker role: Quantitative MRD monitoring for RUNX1::RUNX1T1 and CBFB::MYH11 transcripts after induction and consolidation is among the most robust predictors of relapse in this subgroup, guiding decisions on consolidation intensity and transplant eligibility. Co-mutation profiling (KIT, FLT3, RAS, ASXL2) refines risk stratification within this group [7,8].
JAK2 V617F & JAK Inhibitors
JAK2 V617F is present in approximately 95% of polycythemia vera (PF), and 50–60% of essential thrombocythemia (ET) and primary myelofibrosis (PM) cases, and is the molecular cornerstone for the diagnosis of BCR-ABL1-negative, CALR-and MPL-mutated myeloproliferative neoplasm (MPN) [9]. The first generation JAK1/2 inhibitor Ruxolitinib remains the reference standard for intermediate and high-risk myelofibrosis. Fedratinib, a more selective second generation JAK2 inhibitor, demonstrated superiority over best available therapy in the FREEDOM2 phase 3 trial after ruxolitinib failure [9]. Pacritinib, combining JAK2/FLT3/IRAK1 inhibition, addresses the unmet need in MF patients with severe thrombocytopenia. Next-generation strategies include type II and allosteric inhibitors targeting the V617F pseudokinase domain, aiming at clonal reduction beyond symptom control [10].
Biomarker role: JAK2 V617F testing confirms diagnosis across all three classical MPN entities. Allelic burden quantification at baseline provides prognostic context and tracks clonal dynamics on therapy. In JAK2-negative patients, testing for CALR and MPL mutations is required to complete the diagnostic algorithm. Co-mutation profiling (ASXL1, EZH2, IDH1/2, SRSF2) contributes independently to prognostic risk scoring and transplant eligibility assessment [9,10].
Conclusion
For clinicians, molecular biologists, and diagnostic stakeholders, the challenge is no longer scientific validation but implementation. Aligning clinical evidence, regulatory communication, and reimbursement frameworks is essential to move germline pharmacogenetic testing from selective use to routine preemptive care.
Through the genome lens, pharmacogenetics emerges as a cornerstone of precision medicine—capable of improving drug safety, optimizing therapeutic outcomes, and supporting more sustainable healthcare systems.
References
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood. 2022;140(12):1345–1377.
- Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours. Leukemia. 2022;36(7):1720–1748.
- Dali SA, Al-Mashdali AF, Kalfah A, et al. Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review. Crit Rev Oncol Hematol. 2025;213:104783.
- George B, Chan KH, Rios A. Therapeutic options for CML following failure of second-generation TKI therapy. Front Oncol. 2024;14:1446517.
- Abddaoui M et al. Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management. Hematol Rep. 2025 Nov 28;17(6):66.
- Platzbecker U, et al. (APOLLO Trial). Arsenic Trioxide and ATRA Combination Therapy for High-Risk APL. J Clin Oncol. 2025;43(29):3160–3169.
- Han Yu P et al. Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions. Biochem Pharmacol. 2025 Mar;233:116774.
- Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021 Jun 16;11(6):114.
- Coltoff A, Mascarenhas J. Fedratinib in 2025 and beyond: indications and future applications. Blood Adv. 2025 Apr 22;9(8):1907-1915. doi: 10.1182/bloodadvances.2024015365. PMID: 39951613; PMCID: PMC12008686.
- Nair PC et al. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discov. 2023 Sep 1;4(5):352-364.
- Rataj J, Gorecki L, Muthna D, et al. Targeting FLT3 in AML: novel molecular approaches and therapeutic challenges. Biomed Pharmacother. 2025;182:117788.
- Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300–2309.
- Iqbal U and Shallis RM. Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia. Front. Cell Dev. Biol. 2026 ;14:1779094.
- Ghosh K, Ghosh K. Monoclonal antibodies used for the management of hematological disorders. Expert Rev Hematol. 2022;15(5):443–455.
- Pophali P, Varela JC, Rosenblatt J. Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol. 2024;14:1323914.